Showing posts with label osteoarthritis. Show all posts
Showing posts with label osteoarthritis. Show all posts

Wednesday, December 16, 2015

Lithium chloride could offer effective treatment against osteoarthritis

Bioengineers from Queen Mary University of London (QMUL) have shown for the first time that lithium chloride, a common drug used to treat mental health disorders, could offer an effective treatment against osteoarthritis by disrupting the length of the cells' antennae called primary cilia.

Publishing in the journal FASEB, the scientists show that medical manipulation of the primary cilia, which are tiny hair-like structures protruding from the surface of most human cells, disrupts a key biological process called 'Hedgehog Signalling'.

Osteoarthritis is a painful disease affecting millions of people. It results from the cartilage breaking down at the joints and leads to difficulties in moving around and being active. Being able to control Hedgehog Signalling has previously been shown to reduce the severity of arthritis.

Monday, December 23, 2013

University of Sydney researchers identify new type of medication for osteoporosis

University of Sydney researchers have discovered a new and promising treatment for osteoporosis which is easily delivered in water soluble form. 

After more than four years of investigation, researchers from the Ageing Bone Research Program (Sydney Medical School’s Nepean campus), have found the treatment has shown very promising results in animal experiments. 

The compound is called picolinic acid, a product derived of the essential amino acid tryptophan. 

Lead researcher Professor Gustavo Duque said the odorless compound can be easily dissolved in water. 

“This is a major step in the development of a completely new type of medication for osteoporosis,” he said. 

“Instead of stopping bone destruction, our compound instead stimulates bone formation."
“The product is easily dissolved in water, has a higher level of absorption and did not induce any side effects in the treated mice."

“When this medication was administered in the water of normal and menopausal mice, picolinic acid strongly and safely increased bone mass in normal mice and rescued bone from menopause-associated osteoporosis.”

Professor Duque said the team had patented the compound and will expand their trials to humans in the near future in a bid to address the increasing numbers of people developing the condition. 

“Osteoporosis affects an estimated 300 million people worldwide. One in three women over 50 will experience osteoporotic fractures, as will one in five men."

Friday, July 26, 2013

Urocortin molecule protects cells from osteoarthritis, say researchers

We know that, Urocortin is a protein that in humans is encoded by the UCN gene. This gene is a member of the sauvagine/corticotropin-releasing factor/urotensin I family. It is structurally related to the corticotropin-releasing factor (CRF) gene and the encoded product is an endogenous ligand for CRF type 2 receptors. In the brain, it may be responsible for the effects of stress on appetite. In spite of the gene family name similarity, the product of this gene has no sequence similarity to urotensin II. Urocortin is a potent anorexigenic peptide of 40 amino acids that induces fed-like motor activity when administered centrally or peripherally in fasted animals. Urocortin belongs to the corticotropin-releasing factor (CRF) family that includes CRFurotensin Isauvagineurocortin II and urocortin III. Urocortin is also a potent and long-lasting hypotensive agent and increases coronary blood flow.

Now researchers from The University of Manchester and the University of Westminster have found that the molecule, known as Urocortin, protects cells in the joints from being destroyed.
The discovery could help lead to the development of new medicines to prevent joint degradation  a condition which affects millions of people in the UK each year.